Table 5 Basic modelling and patient information of papers included in systematic review
From: Prediction of resistance to chemotherapy in ovarian cancer: a systematic review
Study | Patient prior chemotherapy treatment | Model accounts for the different chemotherapies? | Prognostic or predictive? | Model validated? |
|---|---|---|---|---|
Jeong et al. [22] | Platinum-based | ✓ | Predictive | ✓ |
Lisowska et al. [23] | Platinum/Cyclophosphamide, Platinum/Taxane | ✗ | Prognostic | ✓ |
Roque et al. [24] | NS | ✗ | Prognostic | ✗ |
Li et al. [3] | Platinum/Cyclophosphamide, Platinum/Taxane | ✗ | Prognostic | ✗ |
Schwede et al. [25] | NS | ✗ | Prognostic | ✓ |
Verhaak et al. [26] | NS | ✗ | Prognostic | ✓ |
Obermayr et al. [27] | Platinum-based | ✗ | Prognostic | ✗ |
Han et al. [28] | Platinum/Paclitaxel | Prognostic | ✓ | |
Hsu et al. [29] | Platinum/Paclitaxel | |||
+ additional treatments | ✓ | Prognostic | ✓ | |
Lui et al. [30] | NS | ✗ | Prognostic | ✓ |
Kang et al. [31] | Platinum/Taxane | Prognostic | ✓ | |
Gillet et al. [32] | Carboplatin/Paclitaxel | Prognostic | ✓ | |
Ferriss et al. [33] | Platinum-based | ✓ | Predictive | ✓ |
Brun et al. [34] | NS | ✗ | Prognostic | ✗ |
Skirnisdottir and Seidal [35] | Carboplatin/Paclitaxel | Prognostic | ✗ | |
Brenne et al. [36] | NS | ✗ | Prognostic | ✗ |
Sabatier et al. [37] | Platinum-based | ✗ | Prognostic | ✓ |
Gillet et al. [38] | NS | ✗ | Prognostic | ✓ |
Chao et al. [39] | NS | ✗ | Prognostic | ✗ |
Schlumbrecht et al. [40] | Platinum/Taxane | Prognostic | ✗ | |
Glaysher et al. [41] | Platinum, Platinum/Paclitaxel | ✓ | Predictive | ✓ |
Yan et al. [42] | Platinum-based | ✗ | Prognostic | ✗ |
Yoshihara et al. [43] | Platinum/Taxane | Prognostic | ✓ | |
Williams et al. [44] | NS | ✓ | Predictive | ✓ |
Denkert et al. [45] | Carboplatin/Paclitaxel | Prognostic | ✓ | |
Matsumura et al. [46] | Platinum-based | ✓ | Predictive | ✓ |
Crijns et al. [47] | Platinum, Platinum/ | |||
Cyclophosphamide, Platinum/Paclitaxel | ✓ | Prognostic | ✓ | |
Mendiola et al. [48] | Platinum/Taxane | Prognostic | ✓ | |
Gevaert et al. [49] | NS | ✗ | Prognostic | ✓ |
Bachvarov et al. [50] | Carboplatin/Paclitaxel, | |||
Carboplatin/Cyclophosphamide, Cisplatin/Paclitaxel | ✗ | Prognostic | ✓ | |
Netinatsunthorn et al. [51] | Platinum/Cyclophosphamide | Prognostic | ✗ | |
De Smet et al. [52] | Platinum/Cyclophosphamide, Platinum/Paclitaxel | ✗ | Prognostic | ✓ |
Helleman et al. [53] | Platinum/Cyclophosphamide, Platinum-based | ✗ | Prognostic | ✓ |
Spentzos et al. [54] | Platinum/Taxane | Prognostic | ✓ | |
Jazaeri et al. [55] | Carboplatin/Paclitaxel, Cisplatin/Cyclophosphamide, Carboplatin/Docetaxel, Carboplatin | ✗ | Prognostic | ✓ |
Raspollini et al. [56] | Cisplatin/Cyclophosphamide, Carboplatin/Cyclophosphamide, Carboplatin/Paclitaxel | ✗ | Prognostic | ✗ |
Hartmann et al. [57] | Cisplatin/Paclitaxel, Carboplatin/Paclitaxel | ✗ | Prognostic | ✓ |
Spentzos et al. [58] | Platinum/Taxane | Prognostic | ✓ | |
Selvanayagam et al. [59] | Cisplatin/Cyclophosphamide, Carboplatin/Cyclophosphamide, Cisplatin/Paclitaxel | ✗ | Prognostic | ✓ |
Iba et al. [60] | Carboplatin/Paclitaxel | Prognostic | ✗ | |
Kamazawa et al. [61] | Carboplatin/Paclitaxel | Prognostic | ✗ | |
Vogt et al. [62] | Etoposide, Paclitaxel/Epirubicin, Carboplatin/Paclitaxel | ✓ | Predictive | ✗ |